Halozyme CEO Sells $6M More as HALO Tops Analyst Target
Halozyme Therapeutics CEO Helen Torley sold $6.44 million of company stock across three consecutive days ending September 11, 2026, at prices between $107.01 and $108.67—continuing a documented patter
Halozyme CEO Sells $6M More as HALO Tops Analyst Target
NEW YORK, September 15 —
Halozyme Therapeutics, Inc. (HALO) is generating 47.7% revenue growth on 76.3% gross margins, yet the person who knows the business best just sold $6.44 million of stock in three days, at prices already 8.4% above where analysts collectively see fair value. The question is not whether CEO Helen Torley is entitled to monetize options, but whether the timing says something her public statements do not.
- Q2 2026 EPS of $2.28 beat consensus by 25.3%; trailing revenue hit $1.66B, per the August 6 earnings 8-K.
- HALO trades at $107.94, a 10.4x forward P/E, against an analyst consensus target of $99.56.
- Net insider activity over 90 days: zero open-market purchases, $7.14M in open-market sales.
The Royalty Machine Running Hot
Halozyme licenses its rHuPH20 enzyme technology, which enables subcutaneous delivery of injectable biologics, to partners including Roche, Pfizer, AbbVie, Eli Lilly, and Bristol Myers Squibb under the ENHANZE platform. Approved drugs riding the technology include DARZALEX (multiple myeloma), Phesgo and Herceptin Hylecta (breast cancer), and Ocrevus SC (multiple sclerosis). The model is deliberately capital-light: 423 employees generating $1.66 billion in trailing revenue. Operating cash flow of $819 million against free cash flow of $337 million reflects a business that compounds on partner sales without proportional cost growth. Four quarters of earnings results show a company that mostly beats estimates, including last quarter's 25.3% upside surprise, with one ugly miss in between. The trajectory into this year looked like genuine acceleration.
What the Selling Pattern Actually Shows
Torley's September 9-11 transactions were exercise-and-sells: 60,000 options struck at $18.41 per share, exercised for roughly $1.1 million and immediately sold at $107, $108 for approximately $6.44 million in proceeds, a net gain near $5.3 million. The same structure appeared in July, when she sold 1,923 shares acquired at a $12.07 strike, and director Mahesh Krishnan did the same in June at a $38.46 strike. Options granted at these levels were always going to be monetized at some point, that is not the issue. The issue is that across 90 days, no insider has purchased a single share on the open market, while the stock has reached prices that already exceed analyst consensus. Repeated selling at each successive high, with no offsetting conviction buys, is at minimum a neutral signal from people with the best seat in the house.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HALO | $12.3B | 10.4x | +42.3% |
| NBIX | $16.0B | 13.1x | +11.6% |
| PTCT | $5.5B | 24.8x | +11.4% |
| ALNY | $33.5B | 20.0x | -45.8% |
| AGIO | $2.0B | n/a | -9.5% |
| CYTK | $10.1B | n/a | +45.6% |
The Number That Settles This Argument
The tension is genuine: a 10.4x forward P/E on a business growing revenue at nearly 50% is anomalously cheap for a royalty-licensing model with 76.3% gross margins, unless earnings expectations embedded in that multiple are too high, or the $1.95 billion net debt load constrains what the company can do with its cash flows. Short interest at 17.2% of float reflects a real cohort betting the multiple is not as cheap as it looks. The next earnings release is the natural stress test: if EPS extends the beat pattern again and the stock holds above $99, the argument that Torley's sales represent informed ceiling-calling weakens considerably. If guidance disappoints, the 17.2% short interest becomes a tailwind for sellers. Run the free Halozyme Therapeutics, Inc. deep-dive → for the latest numbers before that print arrives.
Current fundamentals, valuation and filing history for Halozyme Therapeutics, Inc. (HALO) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Halozyme Therapeutics CEO Helen Torley sold $6.44 million of company stock across three consecutive days ending September 11, 2026, at prices between $107.01 and $108.67—continuing a documented pattern of open-market sales that began when the stock was trading nearly 30% lower, and occurring while HALO already trades 8.4% above the analyst consensus price target of $99.56.